OSI Pharm announces "positive" results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301

Co announces that Prosidion, its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics, reported positive results from a metformin drug interaction study in healthy volunteers with its dipeptidyl peptidase-IV (DP-IV) inhibitor, PSN9301. Exposure to PSN9301 and metformin did not change to a clinically relevant extent when they were co-administered, compared with each therapy alone. "This positive result supports future clinical studies of PSN9301 in combination with metformin, which is what we believe to be the ideal clinical positioning for DP-IV inhibitors," stated Anker Lundemose, M.D., Ph.D., President of Prosidion. "Furthermore, the short systemic duration of action of PSN9301, its principal differentiation from other DP-IV inhibitors, was not changed by combination with metformin. We continue to believe that prandial dosed PSN9301 at breakfast and dinner will ultimately demonstrate equivalent efficacy to once-daily DP-IV inhibitors while reducing the likelihood of any potential side-effects arising from inappropriate increases in levels of DP-IV substrates other than GLP-1 between meals and overnight."